International Collaboration Study on the Racial Difference in Coronary Vasospasm

1.我们已经证明Rho激酶实质上参与了冠状动脉痉挛的分子机制。我们已经证明Rho激酶不仅参与心外膜血管痉挛的分子机制，而且参与微血管痉挛的分子机制.我们已经证明，长期抑制Rho激酶导致冠状动脉粥样硬化和冠状动脉痉挛的消退。我们已经鉴定了Rho激酶催化结构域中的新SNP G930T，并证明该SNP与Rho激酶活性的增强相关。我们已经证实，T930等位基因的频率在冠状动脉痉挛患者中显著高于无痉挛者或对照组。我们进一步证明了这种SNP在患有心绞痛的高加索患者中没有发现。综上所述，这些结果表明，G930 T的相对较高的频率可以解释，至少部分地，日本和高加索人群之间冠状动脉血管痉挛患病率的种族差异。我们已经发表了关于Rho激酶治疗重要性的英文综述。

1. We have demonstrated that Rho-kinase is substantially involved in the molecular mechanism for coronary vasospasm.2. We have demonstrated that Rho-kinase is substantially involved in the molecular mechanism fornot only epicardial vasospasm but also microvascular vasospasm.3. We have demonstrated that long-term inhibition of Rho-kinase causes a regression of both coronary arteriosclerosis and coronary vasospasm.4. We have identified the novel SNP of Rho-kinase, G930T in its catalytic domain and have demonstrated that this SNP is associated with an enhancement of Rho-kinase activity.5. We have demonstrated that the frequency of the T930allele is significantly higher in patients with coronary vasospasm than in those without the spasm or controls. We have further demonstrated that this SNP is not noted in Caucasian patients with angina pectoris.6. Taken together, those results suggest that the relatively higher frequency of G930T could explain, at least in part, the racial difference in the prevalence of coronary vasospasm between Japanese and Caucasian populations.7. We have published the English review regarding the therapeutic importance of Rho-kinase.